Journal of The Korean Dental Society of Anesthesiology (대한치과마취과학회지)

The Korean Dental Society of Anesthsiology (대한치과마취과학회)
권호 표지

Oxycodone: A New Therapeutic Option in Postoperative Pain Management

술후 통증조절을 위한 새로운 대안으로서의 Oxycodone

  • Choi, Byung Moon (Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 최병문 (울산대학교 의과대학 마취통증의학과)
  • Received : 2013.12.23
  • Accepted : 2014.01.02
  • Published : 2013.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Oxycodone is a semi-synthetic opioid synthesized from poppy-derived thebaine. It is a narcotic analgesic generally indicated for relief of moderate to severe pain. Although developed in an attempt to improve on the existing opioids, the adverse effects of oxycodone are those that are typically found in opioids. In recent years, the use of the opioid oxycodone has increased markedly and replacing morphine as the first line choice of opioid in several countries. There are formulations for oral immediate, oral extended release and intravenous use. In 2013, intravenous oxycodone was approved for marketing by Ministry of Food and Drug Safety (MFDS), with the indication of postoperative intravenous patient-controlled analgesia (IV PAC). Simulation study of oxycodone demonstrated that minimum effective analgesic concentration (MEAC) of oxycodone was most quickly reached with higher loading dose and IV PCA with background infusion, which may reduce the necessity of rescue analgesics during immediate postoperative period. Previous studies for postoperative pain management with intravenous oxycodone are limited in sample size, mostly less than 100 patients, which may not be large enough to assess safety of intravenous oxycodone. The effectiveness and tolerability of IV PCA with oxycodone should, therefore, be evaluated in large scale clinical trials in Korean populations.

Keywords

References

  1. Sneader W. Drug Discovery: A History. Hoboken, NJ, Wiley. 2005.
  2. Kalso E. Oxycodone. J Pain Symptom Manage 2005; 29(5 Suppl): S47-56. https://doi.org/10.1016/j.jpainsymman.2005.01.010
  3. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY and Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79(5): 461-79. https://doi.org/10.1016/j.clpt.2006.01.009
  4. Ross FB and Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997; 73(2): 151-7. https://doi.org/10.1016/S0304-3959(97)00093-6
  5. Smith MT. Differences between and combinations of opioids re-visited. Curr Opin Anaesthesiol 2008; 21(5): 596-601. https://doi.org/10.1097/ACO.0b013e32830a4c4a
  6. Nozaki C and Kamei J. Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice. Eur J Pharmacol 2007; 560(2-3): 160-2. https://doi.org/10.1016/j.ejphar.2007.01.021
  7. Silvasti M, Rosenberg P, Seppala T, Svartling N and Pitkanen M. Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta Anaesthesiol Scand 1998; 42(5): 576-80. https://doi.org/10.1111/j.1399-6576.1998.tb05169.x
  8. Brittain GJ. Dihydrohydroxycodeinone pectinate. Lancet 1959; 2(7102): 544-6.
  9. Koch S, Ahlburg P, Spangsberg N, Brock B, Tonnesen E and Nikolajsen L. Oxycodone vs. fentanyl in the treatment of early post-operative pain after laparoscopic cholecy stectomy: a randomised double-blind study. Acta Anaesthesiol Scand 2008; 52(6): 845-50. https://doi.org/10.1111/j.1399-6576.2008.01643.x
  10. Kokki M, Broms S, Eskelinen M, Rasanen I, Ojanpera I and Kokki H. Analgesicconcentrations of oxycodone--a prospective clinical PK/PD study in patients with laparoscopic cholecystectomy. Basic Clin Pharmacol Toxicol 2012; 110(5): 469-75. https://doi.org/10.1111/j.1742-7843.2011.00839.x
  11. Pesonen A, Suojaranta-Ylinen R, Hammaren E, Tarkkila P, Seppala T and Rosenberg PH. Comparison of effects and plasma concentrations of opioids between elderly and middle-aged patients after cardiac surgery. Acta Anaesthesiol Scand 2009; 53(1): 101-8. https://doi.org/10.1111/j.1399-6576.2008.01819.x
  12. Camu F and Vanlersberghe C. Pharmacology of systemic analgesics. Best Pract Res Clin Anaesthesiol 2002; 16(4): 475-88. https://doi.org/10.1053/bean.2002.0262
  13. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ and Armstrong PJ. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. Anesth Analg 1988; 67(4): 329-37.
  14. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K and Olkkola KT. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig 2011; 31(3): 143-53. https://doi.org/10.2165/11539950-000000000-00000
  15. Korjamo T, Tolonen A, Ranta VP, Turpeinen M and Kokki H. Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance. Front Pharmacol 2011; 2: 87.
  16. Soderberg Lofdal KC, Andersson ML and Gustafsson LL. Cytochrome p450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs 2013; 73(6): 533-43. https://doi.org/10.1007/s40265-013-0036-0
  17. Kalso E. How different is oxycodone from morphine? Pain 2007; 132(3): 227-8. https://doi.org/10.1016/j.pain.2007.09.027
  18. Nieminen TH, Hagelberg NM, Saari TI, Pertovaara A, Neuvonen M, Laine K, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009; 110(6): 1371-8. https://doi.org/10.1097/ALN.0b013e31819faa54
  19. Saari TI, Gronlund J, Hagelberg NM, Neuvonen M, Laine K, Neuvonen PJ, et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur J Clin Pharmacol 2010; 66(4): 387-97. https://doi.org/10.1007/s00228-009-0775-8
  20. Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K and Sindrup SH. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010; 54(2): 232-40. https://doi.org/10.1111/j.1399-6576.2009.02104.x
  21. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F and Musshoff F. CYP2D6 genotype dependent oxycodone metabolism inpostoperative patients. PLoS One 2013; 8(3): e60239. https://doi.org/10.1371/journal.pone.0060239
  22. Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM and Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 1998; 8(4): 325-33. https://doi.org/10.1097/00008571-199808000-00006
  23. Xie HG, Kim RB, Wood AJ and Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50. https://doi.org/10.1146/annurev.pharmtox.41.1.815
  24. Heim MH and Meyer UA. Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14(1): 49-58. https://doi.org/10.1016/S0888-7543(05)80282-4
  25. Garcia-Barcelo M, Chow LY, Lam KL, Chiu HF, Wing YK and Waye MM. Occurrence of CYP2D6 gene duplication in Hong Kong Chinese. Clin Chem 2000; 46(9): 1411-3.
  26. Kubota T, Yamaura Y, Ohkawa N, Hara H and Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50(1): 31-4.
  27. Lee SJ, Lee SS, Jung HJ, Kim HS, Park SJ, Yeo CW, et al. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 2009; 37(7): 1464-70. https://doi.org/10.1124/dmd.108.022368
  28. Bertilsson L, Dahl ML, Dalen P and Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53(2): 111-22. https://doi.org/10.1046/j.0306-5251.2001.01548.x
  29. Lennard MS, Iyun AO, Jackson PR, Tucker GT and Woods HF. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2(2): 89-92. https://doi.org/10.1097/00008571-199204000-00006
  30. Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7(3): 193-202. https://doi.org/10.1097/00008571-199706000-00004
  31. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL and Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequencydata. Pharmacogenetics 1999; 9(6): 669-82. https://doi.org/10.1097/01213011-199912000-00002
  32. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3(2): 229-43. https://doi.org/10.1517/14622416.3.2.229
  33. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, et al. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging 2011; 28(1): 41-50. https://doi.org/10.2165/11586140-000000000-00000
  34. Saari TI, Ihmsen H, Neuvonen PJ, Olkkola KT and Schwilden H. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth 2012; 108(3): 491-8. https://doi.org/10.1093/bja/aer395
  35. Ordonez Gallego A, Gonzalez Baron M and Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007; 9(5): 298-307. https://doi.org/10.1007/s12094-007-0057-9
  36. Poyhia R, Vainio A and Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8(2): 63-7. https://doi.org/10.1016/0885-3924(93)90101-Z
  37. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41(2): 67-76. https://doi.org/10.1080/03602530902722679
  38. Shi S, Morike K and Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008; 64(2): 183-99. https://doi.org/10.1007/s00228-007-0422-1
  39. Scott JC and Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987; 240(1): 159-66.
  40. Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE and Raeder J. A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg 2009; 109(4): 1279-83. https://doi.org/10.1213/ane.0b013e3181b0f0bb
  41. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I and Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35(7): 642-6. https://doi.org/10.1111/j.1399-6576.1991.tb03364.x